Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) Overview | 6 | 1 |
| Therapeutics Development | 7 | 4 |
| Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) Products under Development by Stage of Development | 7 | 1 |
| Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) Products under Development by Therapy Area | 8 | 1 |
| Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) Products under Development by Indication | 9 | 2 |
| Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) Products under Development by Companies | 13 | 2 |
| Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) Products under Development by Universities/Institutes | 15 | 2 |
| Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) Therapeutics Assessment | 17 | 6 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 1 |
| Assessment by Route of Administration | 19 | 2 |
| Assessment by Molecule Type | 21 | 2 |
| Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) Companies Involved in Therapeutics Development | 23 | 4 |
| Gilead Sciences, Inc. | 24 | 1 |
| Kyowa Hakko Kirin Co., Ltd. | 25 | 1 |
| Takeda Pharmaceutical Company Limited | 26 | 1 |
| Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) Drug Profiles | 27 | 9 |
| CS-410 Drug Profile | 27 | 1 |
| GS-444217 Drug Profile | 28 | 1 |
| GS-459679 Drug Profile | 29 | 1 |
| selonsertib Drug Profile | 30 | 1 |
| selonsertib + simtuzumab Drug Profile | 31 | 1 |
| Small Molecule to Inhibit ASK-1 for Chronic Pain Drug Profile | 32 | 1 |
| Small Molecule to Inhibit ASK1 for Thrombosis Drug Profile | 33 | 1 |
| Small Molecules to Inhibit Apoptosis Signal-Regulating Kinase 1 Drug Profile | 34 | 1 |
| Small Molecules to Inhibit ASK1 for Amyotropic Lateral Sclerosis Drug Profile | 35 | 1 |
| Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) Featured News &Press Releases | 36 | 1 |
| Apr 16, 2016: Gilead Presents New Data on GS-4997 at The International Liver Congress 2016 | 36 | 1 |
| Appendix | 37 | 2 |
| Methodology | 37 | 1 |
| Coverage | 37 | 1 |
| Secondary Research | 37 | 1 |
| Primary Research | 37 | 1 |
| Expert Panel Validation | 37 | 1 |
| Contact Us | 37 | 1 |
| Disclaimer | 38 | 1 |